Understanding Genetic Heterogeneity in Gene-Edited HSC Products.

CRISPR/Cas gene editing has transformed genetic research and is poised to drive the next generation of gene therapies targeting hematopoietic stem cells (HSCs). However, the installation of the 'desired' edit is most often only achieved in a minor subset of alleles. The array of cellular pathways triggered by gene editing tools produces a broad spectrum of 'undesired' editing outcomes, including short insertions and deletions (indels) and chromosome rearrangements, leading to considerable genetic heterogeneity in gene edited HSC populations. This heterogeneity may undermine the effect of the genetic intervention, since only a subset of cells will carry the intended modification. Also, undesired mutations represent a potential safety concern as gene editing advances toward broader clinical use. Here, we will review the different sources of 'undesired' edits and will discuss strategies for their mitigation and control.

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.